Semaglutide

GLP-1 drugs: clinical trends, safety, and market shifts

246 clusters · 891 sources · last updated about 21 hours ago

Latest: Medical experts propose management system for GLP-1 obesity drugs

Since mid-2026, the expansion of GLP-1 agents for obesity has been accompanied by intensified safety monitoring and evolving clinical data. Research suggests secondary benefits, including a 21% lower risk of fragility fr

Expanded therapeutic research on metformin and semaglutide

11 clusters · 92 sources · last updated 3 days ago

Latest: Semaglutide linked to significant reduction in asthma and COPD attacks

Recent medical research has identified expanded therapeutic potential for diabetes and obesity medications, specifically metformin and semaglutide, regarding brain health, organ function, and aging. Studies from Baylor C

GLP-1 obesity drug rollout and market expansion

103 clusters · 507 sources · last updated 4 days ago

Latest: Novo Nordisk expands obesity drug market in Mexico

Novo Nordisk continues to expand its GLP-1 market presence, maintaining approximately a 43% global market share for obesity and diabetes treatments despite competition from Eli Lilly. The oral Wegovy pill remains a prima

Semaglutide regulatory approvals and pricing in Brazil

6 clusters · 107 sources · last updated 7 days ago

Latest: Mantecorp launches Semavy semaglutide medication in Brazil

Brazil’s National Health Surveillance Agency (Anvisa) has expanded the domestic market for semaglutide, a medication used to treat type 2 diabetes and weight loss. Initially, Anvisa registered five new semaglutide inject

US FDA and regulators tighten oversight of peptide compounds

13 clusters · 89 sources · last updated 27 days ago

Latest: US health officials consider relaxing peptide regulations

The FDA’s Pharmacy Compounding Advisory Committee (PCAC) has continued to evaluate injectable synthetic peptides that have surged in the wellness market. After a narrow 8‑6 vote on July 28, 2026, to recommend six of seve